U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4 - Sarepta Therapeutics
- news.google.com language
- 2025-06-04 20:30 event
- 4 days ago schedule